CROWN BIOSCIENCE



Advance Your Immunotherapy Drug Discovery

Translational Immuno-Oncology platform technologies to support your transition into the clinic.

A JSR Life Sciences Company

QUICKFACT

V1.0

We provides a range of integrated platform technologies for preclinical drug development over a variety of different cancer types. Our immuno-oncology portfolio employs integrated *In vivo, in vitro* and *ex vivo* models along with innovative immunological analyses to inform preclinical decision making and help you confidently:

- Select qualified immunotherapy lead agents
- Assess PK/PD and cytotoxicity of immunotherapies
- Determine efficacy and response to treatment (including *in vitro* and *in vivo* models of resistance)
- Investigate combination therapies

Animal Models

- Syngeneic models (including bioluminescent models)
- Syngeneic NK models
- Murine allograft models (**MuPrime™**)
- Drug target humanized models (**HuGEMM™**/**HuCell™**)
- Humanized mice
- GEMM
- **MiXeno™** transient humanized models
- PDX-non-T-I/O models
- CAR-T therapy evaluation - PDX/CD19 targeting
- Oncolytic virus - PDX/cell line derived xenograft/syngeneic

Immunological Assays

- Phenotypic assays
- *In vitro* screening assays
- Tissue slides/arrays
- Mouse I/O RNA-Seq Panel: transcriptomic insights into tumors, TME, and immune response
- Immunohistochemistry
- FACS
- T cell based assays
- ADCC and CDC
- NK cell antibody-dependent cell-mediated cytotoxicity
- Complement-dependent cytotoxicity
- Luminex and MesoScale Discovery Development





Get in touch

Sales
US: +1 858 622 2900
UK: +44 870 166 6234
busdev@crownbio.com
www.crownbio.com

Science
consultation@crownbio.com